Tvardi Therapeutics operates as an advanced biopharmaceutical company, specializing in the creation of innovative, orally delivered small molecule treatments. These therapies are designed to modulate the STAT3 pathway, with the objective of tackling fibrosis-related illnesses that currently suffer from a substantial lack of effective medical solutions. Their flagship compound, TTI-101, is presently progressing through Phase 2 clinical studies for its potential in treating both idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
